Leucine and Glutamic Acid as a Biomarker of Sarcopenic Risk in Japanese People with Type 2 Diabetes
-
Published:2023-05-21
Issue:10
Volume:15
Page:2400
-
ISSN:2072-6643
-
Container-title:Nutrients
-
language:en
-
Short-container-title:Nutrients
Author:
Nakajima Hanako1ORCID, Okada Hiroshi1ORCID, Kobayashi Ayaka1, Takahashi Fuyuko2, Okamura Takuro1ORCID, Hashimoto Yoshitaka3ORCID, Nakanishi Naoko1, Senmaru Takafumi1, Ushigome Emi1ORCID, Hamaguchi Masahide1ORCID, Fukui Michiaki1ORCID
Affiliation:
1. Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-0841, Japan 2. Nutrition Division, Saiseikai Suita Hospital, Osaka 564-0013, Japan 3. Department of Diabetes and Endocrinology, Matsushita Memorial Hospital, Osaka 570-8540, Japan
Abstract
This study aimed to identify the serum metabolites associated with sarcopenic risk in Japanese patients with type 2 diabetes, determine the effect of dietary protein intake on the serum metabolic profile, and examine its association with sarcopenia. Ninety-nine Japanese patients with type 2 diabetes were included, and sarcopenic risk was defined as low muscle mass or strength. Seventeen serum metabolites were quantified after gas chromatography–mass spectrometry analysis. The relationship between dietary protein intake and the metabolites concerning sarcopenia was analyzed, and the factors affecting sarcopenic risk were clarified. Twenty-seven patients were classified as being at risk of sarcopenia, the same as the general risk, which was associated with older age, a longer duration of the disease, and a lower body mass index. Low levels of leucine and glutamic acid were significantly associated with low muscle strength (p = 0.002 and p < 0.001, respectively), and leucine was also associated with muscle mass (p = 0.001). Lower levels of glutamic acid had higher odds of sarcopenic risk after being adjusted for age and HbA1c (adjusted OR 4.27, 95% CI 1.07–17.11, p = 0.041), but not for leucine. Leucine and glutamic acid can serve as useful biomarkers for sarcopenia, highlighting potential targets for its prevention.
Funder
Danone Institutes Research Grant
Subject
Food Science,Nutrition and Dietetics
Reference32 articles.
1. Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Muscoli, C., Ilari, S., Mollace, V., Della Morte, D., Bellia, A., and Di Daniele, N. (2023). Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease. Int. J. Mol. Sci., 24. 2. Sarcopenia and Chronic Complications of Type 2 Diabetes Mellitus;Purnamasari;Rev. Diabet. Stud.,2022 3. Izzo, A., Massimino, E., Riccardi, G., and Della, P. (2021). A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. Nutrients, 13. 4. Type 2 Diabetes Is Associated with Low Muscle Mass in Older Adults;Kim;Geriatr. Gerontol. Int.,2014 5. Pollakova, D., Tubili, C., Folco, U., Giuseppe, R., Battino, M., and Giampieri, F. (2023). Muscular Involvement in Long Term Type 1 Diabetes: Does It Represent an Underestimated Complication?. Nutrition, 112060. in press.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|